Systematic investigation of the prognostic value of cell division cycle-associated proteins for clear cell renal cell carcinoma patients

Biomark Med. 2020 Feb;14(3):223-238. doi: 10.2217/bmm-2019-0498. Epub 2020 Jan 20.

Abstract

Aim: To explore the prognostic value of the cell division cycle-associated proteins (CDCA) family in clear cell renal cell carcinoma. Methods: Gene profiles were collected from the The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma (TCGA-KIRC), the GSE29609 and GSE22541 datasets. Genetic alteration and DNA methylation data were downloaded from the cBioPortal and MethSurv. The functional enrichment data were analyzed by Metascape. Results: The mRNA expression of the CDCAs, except CBX2, was significantly increased in clear cell renal cell carcinoma patients. Genetic alterations might affect the expression of CDCAs, but promotor methylation does not affect CDCA gene expression. The overall expression of the CDCAs, according to the The Cancer Genome Atlas-KIRC database (hazard ratio [HR]: 2.18), the GSE29609 (HR: 6.08) and GSE22541 (HR: 6.73), was significantly associated with unfavorable overall survival. In addition, genes co-expressed with CDCAs (R2 ≥0.3) were highly associated with cell division and the FOXM1 pathway. Conclusion: Our study demonstrated that the aberrant expression of CDCA gene family members plays an indispensable role in tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell / diagnosis*
  • Carcinoma, Renal Cell / genetics*
  • Carcinoma, Renal Cell / pathology
  • Cell Cycle Proteins / genetics*
  • Databases, Genetic
  • Gene Expression Profiling*
  • Humans
  • Kidney Neoplasms / diagnosis*
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / pathology
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis

Substances

  • Cell Cycle Proteins